Why lead a 3 mg review with a Fiji island trial instead of a COVID paper?
Ivermectin 3 mg reviews that start with a mite count
Wrong review question: does the tablet work. Right review question: work against which organism, at what mcg/kg, on which endpoint, at an exposure a 3 mg stack can actually hit.
This desk Marks burrows before it Marks a headline. Classic scabies is a mite with a usable glutamate-gated chloride channel. Oral ivermectin is not FDA-approved for that mite, but CDC clinical-care language treats two 200 mcg/kg nights, 7 to 14 days apart, taken with food, as an effective alternative to permethrin. A 3 mg review that skips the second night is an incomplete review. Eggs hatch. The first stack does not finish the job.
Population evidence is not a tweet. The Skin Health Intervention Fiji Trial - SHIFT, Romani and colleagues, NEJM 2015 - assigned three island communities to standard care, mass permethrin, or an ivermectin-based mass pass. At twelve months, scabies prevalence in the ivermectin group fell from 32.1 percent to 1.9 percent, a 94 percent relative reduction. Impetigo fell 67 percent. A 24-month follow-up still showed an 89 percent relative cut from baseline. That is the kind of count a 3 mg review should lead with.
If you want the chip-by-chip arithmetic for a single household, that lives in the two-night counting guide. If you want how the chip got cheap enough to run a village pass, that lives in the Kawana price essay. This page's job is the ledger: which endpoints moved, which stayed flat, and why a cough never earned a row next to Stromectol 3 mg.
Cheap 3 mg pills do not buy a COVID file
A low unit price is not an indication. People heard 'cheap, donated, Nobel' and treated that as a virus review. It is not. FDA consumer language at the FDA is blunt: not authorized, not approved for COVID-19, animal products are not human tablets. Available trial data do not show effectiveness against COVID-19 in humans. That sentence is the hold. It is not a vibe.
The labeled oral chip still hits two worms: Strongyloides stercoralis at about 200 mcg/kg once, Onchocerca volvulus at about 150 mcg/kg once. Those rows paid for the tablet. They do not owe a rumor a courtesy listing. Scabies borrows the 200 mcg/kg math off-label, twice. A virus would need a reachable human exposure and a hard clinical endpoint. Platforms ran that test and printed nulls.
So when a shop pitches cheap ivermectin 3 mg as a viral kit, this review files the pitch under wrong organism. Buy, order, or price a 3 mg chip for a named mite or a labeled worm. Do not buy it for a cough. The rest of this essay is the numbers that make that filing boringly ordinary.
SHIFT: 94 percent fewer burrows after a community pass
Romani, Whitfeld, Koroivueta, and colleagues. Three Fijian island communities. 2051 people. Standard care versus mass permethrin versus ivermectin-based mass administration. Primary: change in scabies and impetigo prevalence at twelve months.
Standard care - treat the case and contacts with permethrin - cut scabies from 36.6 percent to 18.8 percent, a 49 percent relative reduction. Mass permethrin cut it from 41.7 percent to 15.8 percent, 62 percent relative. The ivermectin group cut it from 32.1 percent to 1.9 percent, 94 percent relative, 95 percent CI 83 to 100. Impetigo followed the same rank order. Adverse events were mild and more common on ivermectin (15.6 percent versus 6.8 percent on permethrin).
The ivermectin regimen was not a mystery megadose. Participants received an ivermectin-based pass; those with clinical scabies got a second treatment at day 7. That is the two-night logic in public-health clothes: first night knocks live mites, second night catches hatchlings. A household clinic script uses the same 200 mcg/kg math on a 3 mg blister. SHIFT scaled it to an island.
At 24 months the ivermectin community still sat at 3.6 percent prevalence, an 89 percent relative reduction from baseline. Permethrin and standard-care islands had drifted back higher. Durability is part of a review. A one-month itch score is not. When someone asks whether ivermectin 3 mg 'works for scabies,' this is the citation I put on the blotter before I mention any cough trial.
Why a second 200 mcg/kg night exists
Eggs outlast the first swallow. That is why a 3 mg scabies review that stops at night one is scoring the wrong endpoint. CDC and STI-guideline language therefore repeat the Dose: 200 mcg/kg, with food, then the same count 7 to 14 days later. CDC STI pages at the CDC prefer the 14-day gap in one write-up; clinical-care pages allow 7 to 14. Either way, one night is an incomplete pass.
Food is not a lifestyle tip. The Stromectol label tells worm patients to take the tablet on an empty stomach with water, because a high-fat meal raised bioavailability about 2.5-fold in a 30 mg volunteer study. Scabies experts flip that rule on purpose. They want more drug in the epidermis, so they dose with a meal. Same 3 mg chip. Same 200 mcg/kg. Different Thread: mite in skin versus worm in gut. Mix the fasting rules and you underdose the mite or you wander off the labeled worm PK.
Contacts and laundry sit on the same review card. Treat the household on the same calendar. Hot-wash bedding. Leftover itch for two to four weeks is immune noise, not proof the chips failed. New burrows on previously clear skin are the retreatment trigger. A review that adds a third stack because someone still scratches is not being thorough. It is being sloppy.
The dish micromoles that never fit a 3 mg blister
SARS-CoV-2 does not carry the mite-and-worm channel. A 2020 Vero-cell paper - Caly and colleagues - showed antiviral activity at micromolar concentrations, on the order of 5 micromolar, tens of times above the nanomolar peak a labeled 200 mcg/kg human dose produces. Arithmetic killed the translation before the first platform RCT enrolled. A 3 mg stack cannot honestly chase that well.
People heard 'it killed virus in a dish' and skipped the units. Micromoles in a well are not micrograms per kilogram in a person. Pushing toward dish levels is how you buy hypotension, confusion, and seizures - the same cluster that showed up when veterinary paste entered the story. The compound card at ivermectin holds the PK that makes the concentration gap concrete. Here the job is the trial ledger.
Platforms later tested 400 mcg/kg for three days, 400 mcg/kg for five days, and 600 mcg/kg for six days. Those Doses already sat above the worm label and above a two-night mite pass, and still sat below a honest dish match. That is why a null viral trial is not a conspiracy. It is what the arithmetic predicted. A review that files those nulls next to SHIFT is doing its job. A review that averages them into one 'ivermectin works' headline is not.
TOGETHER's hospital composite stayed flat
Reis and colleagues, NEJM 2022, adaptive platform in Minas Gerais. Ivermectin 400 mcg/kg daily for three days versus placebo. Primary composite: hospital admission or an emergency visit longer than six hours, within 28 days.
Assignment: 679 to ivermectin, 679 to placebo, thousands more to other platform arms. Primary events: 100 of 679 (14.7 percent) versus 111 of 679 (16.3 percent). Relative risk 0.90, 95 percent Bayesian credible interval 0.70 to 1.16. Most events were true admissions. Secondary outcomes did not rescue the drug. Per-protocol and modified intention-to-treat reads stayed null.
That is a large, placebo-controlled, early-treatment outpatient trial in a high-risk group. It is the opposite of a five-patient case series. When someone tells you 'they never tested it properly,' this is the citation you put on the blotter. The Dose was already double the Strongyloides 200 mcg/kg line, given for three days, not one, and already heavier than a two-night mite pass. The endpoint was the endpoint people said they cared about: staying out of hospital.
A 10 percent relative wiggle that crosses 1.0 is not a hidden win. It is noise around a null. Meta-analyses that once looked positive were smaller, messier, and in at least one famous case later withdrawn. TOGETHER's event count exceeded those pooled events. The platform did what a platform is for: it shrank the rumor. A 3 mg review that still leads with a withdrawn preprint is not a review. It is a scrapbook.
I-TECH and ACTIV-6 climbed mcg/kg and still clocked nothing
I-TECH (NCT04920942) was an open-label randomized trial at twenty Malaysian public hospitals plus a quarantine center, May to October 2021. Adults 50 and older, comorbidities, mild-to-moderate COVID-19 in the first week. Ivermectin 0.4 mg/kg - 400 mcg/kg - daily for five days plus standard care, versus standard care alone. Primary analysis: 490 patients, mean age 62.5. Progression to hypoxic disease: 52 of 241 (21.6 percent) on ivermectin versus 43 of 249 (17.3 percent) on control. Relative risk 1.25, 95 percent CI 0.87 to 1.80, P = 0.25. Point estimate ran the wrong way.
ACTIV-6 then moved the post. The 600 mcg/kg arm randomized 1206 US outpatients (602 drug, 604 placebo) from February to July 2022. Median age 48. Most already vaccinated. Targeted 600 mcg/kg daily for six days versus placebo. Median time to sustained recovery: 11 days in both groups. Hazard ratio 1.02. Hospitalization and urgent-care use did not separate. A three-times-labeled Strongyloides Dose, given for six days, still did not shorten the clock. JAMA Internal Medicine published I-TECH in 2022. The 600 mcg/kg ACTIV-6 read followed.
That matters for the 'you underdosed it' Thread. Activists moved the goalposts from 200 mcg/kg to 400, then to 600. Platforms followed the moving post and still printed nulls. You cannot keep doubling a 3 mg stack forever. Neurotoxicity sits on the other side of that dare. The labeled worm Doses and the two-night mite Dose exist because they hit invertebrate channels without knocking the host. A review that keeps asking for 800 mcg/kg is no longer reviewing. It is daring the host.
How this desk files a 3 mg review
| Claim | Dose tested or used | Read |
|---|---|---|
| SHIFT scabies MDA | Ivermectin-based pass; day-7 repeat if infested | 32.1% to 1.9%; 94% relative cut |
| Classic scabies (guideline) | 200 mcg/kg, 3 mg chips, two nights | Off-label oral; treat contacts |
| Strongyloidiasis | 200 mcg/kg once, 3 mg chips | Labeled; confirm stool |
| Onchocerciasis | 150 mcg/kg, 3 mg chips | Labeled; MDA repeats |
| TOGETHER COVID | 400 mcg/kg x 3 days | 14.7% vs 16.3% composite; null |
| I-TECH COVID | 400 mcg/kg x 5 days | 21.6% vs 17.3% progression; null |
| ACTIV-6 COVID | 600 mcg/kg x 6 days | 11 vs 11 days recovery; null |
Mark the organism and the endpoint the investigators pre-registered. Dose the arm they actually gave, in mcg/kg and nights, not in folklore. Thread the rumor that says 'they used the wrong dose' against the fact that viral platforms already climbed from 200 to 600. Point: ivermectin 3 mg reviews score scabies counts. They do not open a viral file.
Evidence rank is ordinary. Cell culture generates questions. Small open studies confound easily. Withdrawn preprints should leave the table. Island MDA and pooled platform RCTs settle practice. Antiparasitic mite and worm indications cleared that bar over years. COVID-19 claims never did at exposures a human 3 mg chip can deliver without neurotoxicity.
Prescribe where the invertebrate target and the mcg/kg evidence align. Do not extrapolate to a virus or to a paste. Off-label megadosing buys toxicity without a parasitic indication. New rows, if they ever appear, will need the same bar these platforms already set. Talk with your own clinician before anyone changes what you take - this is a research point, not a personal plan.
Reader mail
Reader questions on this article
Answered by Dr. Priya Raman, PharmD · Clinical pharmacology & drug safety
Mail after the 3 mg review essay. I will mark the trial name and the mcg/kg. I will not add a COVID line to your blister.
Because SHIFT moved a mite endpoint at a reachable Dose. Prevalence fell from 32.1 percent to 1.9 percent, a 94 percent relative cut, and the 24-month resurvey still sat near 3.6 percent. That is a count. TOGETHER randomized 679 versus 679 at 400 mcg/kg for three days and printed 14.7 percent versus 16.3 percent on a hospital-or-long-ED composite, relative risk 0.90 with a credible interval that crossed 1.0. I file the trial that moved burrows. I close the trial that did not move hospitals. FDA summaries at the FDA match that split.
If it stopped the virus in a lab dish, why did the tablets fail?
Units. Caly's 2020 culture work needed micromolar ivermectin - around 5 micromolar in Vero cells. A labeled 200 mcg/kg human Dose, stacked as 3 mg chips, peaks in the nanomolar range. That is a fifty-fold-plus gap, not a rounding error. Climbing toward the dish is how you buy neurologic toxicity. Platforms already tested 400 and 600 mcg/kg and still saw no clinical win. Lab hit is not achievable PK. That translation failure is common. It is why a 3 mg review never rests on a well.
I-TECH was open-label. Doesn't that make the null weaker?
Open-label can bias toward finding a benefit, not toward hiding one. Patients and clinicians knew who got drug. If hope moved the needle, it should have favored ivermectin. Instead, 21.6 percent progressed versus 17.3 percent on control, relative risk 1.25. Ventilation, ICU, and death did not separate. Design is imperfect. Direction is still null. I pair I-TECH with placebo-controlled TOGETHER and ACTIV-6 rather than discarding it. Together they close the 'nobody studied high-risk adults' claim.
ACTIV-6 used 600 mcg/kg. Isn't that proof they finally used a real dose?
It is proof the goalpost moved and the endpoint still sat still. Six hundred mcg/kg daily for six days is three times the Strongyloides 200 mcg/kg label, and far heavier than a two-night mite pass. Time to sustained recovery did not improve - 11 days versus 11 days. Hospitalization was uncommon and did not split. You cannot keep stacking 3 mg chips until a dish concentration appears. The host will fail first. That arm ended the underdosing Thread for me.
So is there any COVID situation where you would still reach for Stromectol 3 mg?
Only if the same patient also has a labeled or strongly evidenced parasite - Strongyloides before steroids, or a documented mite pass - and the COVID diagnosis is coincidental. I would still count 200 mcg/kg in 3 mg chips for the worm or the two-night mite calendar, not for the virus. I would not add extra days 'for COVID.' FDA has not authorized that row. If a future trial at a tolerable exposure ever turns positive on a hard endpoint, I will rewrite this answer. That trial is not on the shelf now.
Are the scabies and worm indications actually solid, or are you contrasting them for rhetoric?
Solid, on different cards. SHIFT is island-level mite control. Strongyloides cure rates after 200 mcg/kg beat older drugs in comparative work, and you confirm with stool because autoinfection hides. Onchocerciasis MDA at 150 mcg/kg has village-level blindness and transmission data over decades of Mectizan. Those are different evidence species from a 2020 tweet. I am not inflating mites to dunk on a virus. I am refusing to let a null viral claim borrow a parasitic reputation. MedlinePlus pages at MedlinePlus keep the labeled uses short for a reason.
People say regulators blocked a cheap drug. How do you answer that in clinic?
I put the numbers on the blotter. Cheap is true for a 3 mg generic chip. Blocked is false for the worm rows - those are labeled. Scabies is guideline, not a secret. For COVID, platforms funded and run in Brazil, Malaysia, the US, and the UK tested the drug at Doses above the label and printed nulls. A regulator that added a virus row after that ledger would be inventing. Donation history from 1987 does not obligate a new indication. I will mark a cheap antiparasitic. I will not invent a cheap antiviral.
What about meta-analyses that still claim a COVID benefit?
Ask which trials they kept. If they lean on tiny unblinded series or a withdrawn dataset, the pool is decorative. TOGETHER's event count alone outweighed several of those earlier pools. I-TECH and ACTIV-6 add more randomized patients at higher mcg/kg. A meta-analysis is not a trump card over its ingredients. When the largest ingredients are null, I do not let a forest plot launder them. Bring the protocol and the excluded-studies list if you want a longer desk note.
Where do I send a relative who is still taking paste 'just in case'?
To their own clinician, and to the FDA page that says animal products are not human tablets. Paste does not convert cleanly into a 3 mg chip count. The COVID platforms already tested more mcg/kg than a Strongyloides script or a two-night mite pass and found no recovery or hospital win. Remaining on paste adds toxicity risk with no parasitic diagnosis. If they have a real mite, we count chips twice. If they have a cold, we do not. This inbox will not do the conversion.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated